Founded in June 215 and with Headquarter in Nanjing, China, Nanjing RealMind Biotech Co., Ltd. (RealMind Biotech) is national High-Tech Enterprise specialized in the R&D, manufacturing and sales of in vitro diagnostic products. The company has long been committed to providing advanced, fully automated, and compact chemiluminescence immunoassay (CLIA) systems and matching reagents, striving to make a difference for global clinical diagnosis with innovative technology.

RealMind Biotech has made great achievements in the field of compact fully automatic chemiluminescence platforms. Till the end of July 2025, we have achieved a total of 75+ NMPA (National Medical Products Administration) product registration certificates and 100+ CE certifications. In the domestic Chinese market, our customers are distributed across 25 provinces, and over 50% of our end users are among China’s most influential top-tier hospitals. Internationally, we have established partnerships in more than 20 countries spanning Europe, the USA, Latin America, the Middle East, Southeast Asia, and South Asia. Our shareholders include renowned financial institutions such as Sequoia Capital, and RealMind also has two strategic partners: Roche Diagnostics (China) and GeneScience Pharmaceutical.

In line with what our mission conveys: For Better Diagnosis, RealMind Biotech is dedicated to delivering high-quality, precise, and efficient diagnostic solutions to improve global healthcare outcomes.